[
    [
        {
            "time": "2021-05-31",
            "orginal_text": "A股融资融券日报：两融余额增加114.99亿元（5月31日）",
            "features": {
                "keywords": [
                    "两融余额",
                    "增加"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "A股融资融券日报：两融余额增加114.99亿元（5月31日）",
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加114.99亿元（5月31日）",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物月报：“三胎”“七普”相继发布 医药空间广阔 继续把握赛道布局、大小兼备的思路",
            "features": {
                "keywords": [
                    "三胎",
                    "七普",
                    "医药空间",
                    "赛道布局"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "医药生物月报：“三胎”“七普”相继发布 医药空间广阔 继续把握赛道布局、大小兼备的思路",
            "scores": {
                "News_content": "医药生物月报：“三胎”“七普”相继发布 医药空间广阔 继续把握赛道布局、大小兼备的思路",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "orginal_text": "八连阳！定增、回购、重组齐上阵，花样保壳迎转机",
            "features": {
                "keywords": [
                    "八连阳",
                    "定增",
                    "回购",
                    "重组",
                    "保壳"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "八连阳！定增、回购、重组齐上阵，花样保壳迎转机",
            "scores": {
                "News_content": "八连阳！定增、回购、重组齐上阵，花样保壳迎转机",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "复星医药(02196.HK)旗下用于治疗I型神经纤维瘤病新药获美FDA药品临床试验批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "新药",
                    "FDA",
                    "临床试验"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "复星医药(02196.HK)旗下用于治疗I型神经纤维瘤病新药获美FDA药品临床试验批准",
            "scores": {
                "News_content": "复星医药(02196.HK)旗下用于治疗I型神经纤维瘤病新药获美FDA药品临床试验批准",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "【行情】港股抗疫概念板块多数下行，康希诺生物跌超7%，歌礼制药跌近4%，复星医药跌超3%",
            "features": {
                "keywords": [
                    "港股",
                    "抗疫概念",
                    "下行",
                    "康希诺生物",
                    "歌礼制药",
                    "复星医药"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "【行情】港股抗疫概念板块多数下行，康希诺生物跌超7%，歌礼制药跌近4%，复星医药跌超3%",
            "scores": {
                "News_content": "【行情】港股抗疫概念板块多数下行，康希诺生物跌超7%，歌礼制药跌近4%，复星医药跌超3%",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "复星医药(02196.HK)作价人民币约5.53亿出售在建的台州浙东医院",
            "features": {
                "keywords": [
                    "复星医药",
                    "出售",
                    "台州浙东医院"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "original_text": "复星医药(02196.HK)作价人民币约5.53亿出售在建的台州浙东医院",
            "scores": {
                "News_content": "复星医药(02196.HK)作价人民币约5.53亿出售在建的台州浙东医院",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "复星医药(02196.HK)拟斥资人民币250万参与设立合资公司",
            "features": {
                "keywords": [
                    "复星医药",
                    "合资公司",
                    "投资"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "复星医药(02196.HK)拟斥资人民币250万参与设立合资公司",
            "scores": {
                "News_content": "复星医药(02196.HK)拟斥资人民币250万参与设立合资公司",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        }
    ]
]